BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. حسب Luqiong Liu (11537092)

Line graph showing the increase or decrease in the average number of bee swarms caught over the past three years (Mean  حسب Beatrice T. Nganso (4114768)

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. حسب Zahra Hosseininia (22265113)

ECoG timescales decrease during spatial attention. حسب Isabel Raposo (21615517)

"…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …"

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. حسب Peiqi Yin (6533747)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. حسب Ryan J. Treves (13527735)

Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. حسب Luqiong Liu (11537092)

"…<p>(<b>A)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on days 1–22. …"

Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. حسب Luqiong Liu (11537092)

The nsP4-Q192L and C483Y mutations decrease the 4′-FlU sensitivity of both replication and transcription. حسب Peiqi Yin (6533747)

NSC population and proliferation decrease drastically during the second postnatal week of DG development. حسب Cristina Medina-Menéndez (21800157)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)